4 insiders bought €388k of shares over the last 90 days, the latest by 이광인, filed 23 Sept 2026.
Who traded when
BuySale+5 other insiders
Since the insiders bought
- +26.1%Entry ₩73,400 · Close at T+90 ₩92,558
- -31.2%Entry ₩90,200 · Close at T+90 ₩62,100
- +18.2%Entry ₩62,600 · Close at T+90 ₩74,000
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate L&C BIO Co.,Ltd Strong Buy (bullish), based on 2 analysts. Average price target: ₩45,000.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- 428,909 sharesShareKRXDART:20260930000842
- Other0DART
- Other0DART
- 4,590 sharesShareKRXDART:20260923000236Canonical exit: 22 Dec 2026 (T+90)
- 2,142 sharesShareKRXDART:20260923000211Canonical exit: 22 Dec 2026 (T+90)
- 496 sharesShareKRXDART:20260923000209Canonical exit: 22 Dec 2026 (T+90)
- 5,424 sharesShareKRXDART:20260923000205Canonical exit: 22 Dec 2026 (T+90)
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- 400,780 sharesShareKRXDART:20260812000650
- Other0DART
- ●Executives0DART
- 55,023 sharesKRXDART:20260610000475
- 57,528 sharesKRXDART:20260605000441
- 3,324,016 sharesShareKRXDART:20260605000448Canonical exit: 3 Sept 2026 (T+90)
- 100 sharesKRXDART:20260430001843
25 of 100 declarations
About L&C BIO Co.,Ltd
At L&C BIO Co.,Ltd (엘앤씨바이오), the record revolves around the chief executive: 이환철 (대표이사) made 59 of the 86 filings, 40 purchases and 9 sales. Only one of the 50 purchases carries an amount, EUR 111,132, 손석우's (상무) on August 29, 2025; none of the 19 sales has one. Open-market trades are 72% purchases.
The other filers weigh little: the company itself has 5, 나우ib (대량보유자) has 3, with 1 purchase and 2 sales, 한방희 (부사장) has 3, also 1 purchase and 2 sales, and 신성훈 (상무) has 2 purchases. On September 23, 2026, 4 filers bought on the same day.
Read moreShow less
Filings, published from February 23, 2021 to September 30, 2026, number 21 in 2021, 7 in 2024, 14 in 2025 and 20 in 2026, from 14 filers. This health care company is valued at KRW 1.8 trillion, and insiders hold 34.2% of the capital. Over the last 12 months there are 24 filings, 9 purchases and 10 sales. On the 25 filings where the delay is known, a typical filing is published 4 days after the trade. For 41 purchases a 90-day result is stored: a median of minus 2.2%, with 41% of results positive. These are recorded past results, not a forecast.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
